Evidence map›Paper›PMID 35064694›Full record

ArticleSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2022

Micropuncture closure following high density microarray patch application in healthy subjects.

Joakim Henricson, David A Muller, S Ben Baker, Fredrik Iredahl, Totte Togö, Chris D Anderson

Open access · hybridAbstract read
In one paragraph

Article in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Micropuncture closure following high density microarray patch application in healthy subjects.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Joakim HenricsonDepartment of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden.ORCID https://orcid.org/0000-0001-5281-9438
David A MullerSchool of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
S Ben BakerVaxxas Pty Ltd, Translational Research Institute, Woolloongabba, Queensland, Australia.
Fredrik IredahlDepartment of Primary health care, Region Östergötland, Linköping, Sweden.ORCID https://orcid.org/0000-0002-4245-7565
Totte TogöAllergy Centre, Region Östergötland, Linkoping, Sweden.
Chris D AndersonDivision of Cell Biology, Faculty of Health Sciences, Linköping University, Linkoping, Sweden.
Linköping University · SEIndustrial Development Center (Sweden) · SEThe University of Queensland · AUTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe high-density microarray patch (HD-MAP) promises to be a robust vaccination platform with clear advantages for future global societal demands for health care management. The method of action has its base not only in efficient delivery of vaccine but also in the reliable induction of a local innate physical inflammatory response to adjuvant the vaccination process. The application process needs to induce levels of reactivity, which are acceptable to the vaccine, and from which the skin promptly recovers. MATERIALS AND

methods1 × 1 cm HD-MAP patches containing 5000, 250-μm long microprojections were applied to the skin in 12 healthy volunteers. The return of skin barrier function was assessed by transepidermal water loss (TEWL) and reaction to topical histamine challenge.

resultsSkin barrier recovery by 48 h was confirmed for all HD-MAP sites by recovered resistance to the effects of topical histamine application.

conclusionsOur previous observation, that the barrier disruption indicator TEWL returns to normal by 48 h, is supported by this paper's demonstration of return of skin resistance to topical histamine challenge in twelve healthy subjects.

Indexed as

SkinWater Loss, InsensibleHealthy VolunteersHumansPuncturesVaccinationevaporimetrymicroneedlespolarisation reflectance spectroscopyskin barrier integrityskin reactivityvaccination

Identifiers

PMID35064694
PMCPMC9907643
OpenAlexW4207073837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.